Risdiplam is the one orally administered drug approved for the cure of SMA. It had been FDA permitted in 2020 to be used in people two months of age and more mature, and it functions as an SMN2 gene splicing modifier resulting in larger amounts of SMN protein. Oral administration https://2-dimethyl-6-phenylsulfon92467.blogaritma.com/26459521/5-easy-facts-about-su5408-described